相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD)
Kate L. Harris et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
Ralf Reilmann et al.
LANCET NEUROLOGY (2019)
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J. Tabrizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
International Guidelines for the Treatment of Huntington's Disease
Anne-Catherine Bachoud-Levi et al.
FRONTIERS IN NEUROLOGY (2019)
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review
Klaus Seppi et al.
MOVEMENT DISORDERS (2019)
Huntington's disease: a clinical review
P. McColgan et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United States
Victor W. Sung et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis
Caterina Fusilli et al.
LANCET NEUROLOGY (2018)
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
Andrew McGarry et al.
NEUROLOGY (2017)
A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Cysteamine in Huntington's Disease
Christophe Verny et al.
MOVEMENT DISORDERS (2017)
The CREST-E study of creatine for Huntington disease A randomized controlled trial
Steven M. Hersch et al.
NEUROLOGY (2017)
Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate
Andre M. Travessaa et al.
JOURNAL OF HUNTINGTONS DISEASE (2017)
Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort
Filipe Brogueira Rodrigues et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2017)
Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?
Filipe B. Rodrigues et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2017)
The HTT CAG-Expansion Mutation Determines Age at Death but Not Disease Duration in Huntington Disease
Jae Whan Keum et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2016)
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease A Randomized Clinical Trial
Samuel Frank et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial
D. Angus et al.
LANCET NEUROLOGY (2015)
A Randomized, Placebo-Controlled Trial of AFQ056 for the Treatment of Chorea in Huntington's Disease
Ralf Reilmann et al.
MOVEMENT DISORDERS (2015)
Ethyl-Eicosapentaenoic Acid Treatment in Huntington's Disease: A Placebo-Controlled Clinical Trial
Joaquim J. Ferreira et al.
MOVEMENT DISORDERS (2015)
Results of the Citalopram to Enhance Cognition in Huntington Disease Trial
Leigh J. Beglinger et al.
MOVEMENT DISORDERS (2014)
PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Herminia D. Rosas et al.
NEUROLOGY (2014)
Effectiveness of Anti-Psychotics and Related Drugs in the Huntington French-Speaking Group Cohort
Gaelle Desamericq et al.
PLOS ONE (2014)
Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review
Noelle E. Carlozzi et al.
JOURNAL OF HUNTINGTONS DISEASE (2014)
GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes
Gordon Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2013)
A Randomized, Double-Blind, Placebo-Controlled Trial of Pridopidine in Huntington's Disease
Karl Kieburtz et al.
MOVEMENT DISORDERS (2013)
A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease
Karl Kieburtz et al.
JAMA NEUROLOGY (2013)
The incidence and prevalence of Huntington's disease: A systematic review and meta-analysis
Tamara Pringsheim et al.
MOVEMENT DISORDERS (2012)
GRADE guidelines: 9. Rating up the quality of evidence
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE guidelines: 2. Framing the question and deciding on important outcomes
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE guidelines: 7. Rating the quality of evidence-inconsistency
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE guidelines: 3. Rating the quality of evidence
Howard Balshem et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE guidelines: 8. Rating the quality of evidence-indirectness
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE guidelines: 5. Rating the quality of evidence-publication bias
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
Gordon Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias)
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE guidelines 6. Rating the quality of evidence-imprecision
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
Justo Garcia de Yebenes et al.
LANCET NEUROLOGY (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease
Karl Kieburtz et al.
ARCHIVES OF NEUROLOGY (2010)
Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease
Anders Lundin et al.
CLINICAL NEUROPHARMACOLOGY (2010)
A Futility Study of Minocycline in Huntington's Disease
Heidi Schwarz et al.
MOVEMENT DISORDERS (2010)
Patient and caregiver quality of life in Huntington's disease
Rebecca E. Ready et al.
MOVEMENT DISORDERS (2008)
Riluzole in Huntington's disease: A 3-year, randomized controlled study
G. Bernhard Landwehrmeyer et al.
ANNALS OF NEUROLOGY (2007)
Effect of donepezil on motor and cognitive function in Huntington disease
E. Cubo et al.
NEUROLOGY (2006)
Tetrabenazine as antichorea therapy in Huntington disease - A randomized controlled trial
FJ Marshall et al.
NEUROLOGY (2006)
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
SM Hersch et al.
NEUROLOGY (2006)
Ethyl-EPA in Huntington disease - A double-blind, randomized, placebo-controlled trial
BK Puri et al.
NEUROLOGY (2005)
分享论文
